文献速递淋巴瘤造血干细胞移植与细胞治疗

克隆性造血的大克隆影响套细胞淋巴瘤的结局:FIL MCL0208 临床试验结果

Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial.
PubMed 文献 · Blood Adv · 2025-01-01

该研究对 FIL MCL0208 3 期试验中 300 例初治年轻套细胞淋巴瘤患者中的 254 例(85%)基线样本进行二代测序分析克隆性造血(M-CH)。中位随访 7 年后,大克隆(变异等位基因频率≥10%)患者的无进展生存期(HR 2.93,95%CI 1.36-6.31,P=.006)和总生存期(HR 3.02,95%CI 1.21-7.55,P=.018)更差,且大克隆与 ASCT 后血液学恢复时间更长相关(P=.026)。

要点

  • 254/300(85%)例患者有基线样本,34 例(13%)检出至少 1 个 M-CH 候选基因突变,DNMT3A 最常见(54%)。
  • 大克隆(VAF≥10%)相比其他 CH 患者,PFS 的 HR 为 2.93(95%CI 1.36-6.31,P=.006),OS 的 HR 为 3.02(95%CI 1.21-7.55,P=.018)。
  • 竞争风险分析显示大克隆的不良结局与 MCL 进展相关(P<.05),且大克隆患者 ASCT 后血液学恢复时间更长(P=.026)。

核心结论

  • 首次显示大克隆性造血可能与套细胞淋巴瘤患者不良临床结局相关。

研究设计与样本

  • 基于 FIL MCL0208 3 期试验的二代测序分析,评估来那度胺维持对比观察(在化学免疫治疗和自体干细胞移植后)的初治年轻套细胞淋巴瘤患者。
  • 300 例入组患者中 254 例(85%)有基线样本可用于 CH 分析,中位年龄 57 岁(范围 32-66)。

主要发现

  • 34 例(13%)检出至少 1 个 M-CH 候选基因突变,DNMT3A 突变频率最高(54%)。
  • 中位随访 7 年,大克隆(VAF≥10%)相比其他 CH 患者,PFS 更差(HR 2.93,95%CI 1.36-6.31,P=.006),OS 更差(HR 3.02,95%CI 1.21-7.55,P=.018)。
  • 竞争风险分析显示大克隆相关的不良结局与 MCL 进展相关(P<.05)。
  • 大克隆患者 ASCT 后血液学恢复时间比其余队列更长(P=.026)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although recent evidence suggests that myeloid clonal hematopoiesis (M-CH) may influence lymphoma clinical outcome, its impact in mantle cell lymphoma (MCL) remains unclear. Here, we report a comprehensive next-generation sequencing-based analysis of the M-CH mutational landscape at baseline and follow-up in patients enrolled in the Fondazione Italiana Linfomi MCL0208 phase 3 trial, evaluating lenalidomide maintenance vs observation after chemoimmunotherapy and autologous stem cell transplantation (ASCT) in untreated young patients with MCL. Overall, 254 of 300 (85%) enrolled patients (median age, 57 years [range, 32-66]) had a baseline sample available for CH analysis. Using stringent criteria, at least 1 mutation involving M-CH candidate genes was described in 34 patients (13%), with DNMT3A being the most frequently mutated gene (54%). After a median follow-up of 7 years, the presence of large CH clones (variant allele frequency of ≥10%) predicted worse progression-free survival (hazard ratio [HR], 2.93; 95% confidence interval [CI] 1.36-6.31; P = .006) and overall survival (HR, 3.02 [1.21-7.55]; P = .018) compared with patients with CH. Importantly, the competing risks analysis demonstrates that the worse clinical outcome associated with M-CH large clones is linked to MCL progression (P < .05). Moreover, large M-CH clones showed longer time to hematological recovery after ASCT than the remaining cohort (P = .026). In conclusion, we showed for the first time that large CH clones might associate with unfavorable clinical impact in patients with MCL. This trial was registered at www.clinicaltrialsregister.eu as EudraCT (2009-012807-25) and www.ClinicalTrials.gov as #NCT02354313.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ragaini S, Galli A, Genuardi E, et al. Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial. Blood Adv. 2025. PMID: 39808795. doi:10.1182/bloodadvances.2024014948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。